New hope for esophageal cancer: can a 'Maintenance' drug keep the disease at bay?
NCT ID NCT06964568
Summary
This study is testing if a new approach helps people with locally advanced esophageal cancer. After receiving standard chemotherapy and radiation together, some participants will get a follow-up immunotherapy drug (a PD-1 inhibitor) to try to keep the cancer from coming back. The goal is to see if this extra 'maintenance' treatment helps control the disease for a longer period compared to just watching it after the initial treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RADIOTHERAPY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.